Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Comparison of Three Scores for Ultrasound Assessment and Monitoring of Pulmonary Aeration

Conditions:   Atelectasis;   Pneumonia;   Acute Respiratory Distress Syndrome;   Pulmonary Embolism;   Hypoxemia;   Dyspnea
Interventions:   Procedure: Lung ultrasound examination on Day 1 and Day 2 to 4;   Procedure: Lung ultrasound examination on Day 1;   Device: GE Vivid Ultrasound system
Sponsor:   Centre hospitalier de l'Université de Montréal (CHUM)
Not yet recruiting - verified May 2015

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Conditions:   Deep Vein Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Not yet recruiting - verified May 2015

Safety and Efficacy Study of Apixaban to Prevent Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With PEG Asparaginase

Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
Sponsor:   Bristol-Myers Squibb
Recruiting - verified April 2015

CT for Pulmonary Thromboembolic Disease

Condition:   Pulmonary Embolism
Intervention:  
Sponsor:   University of Maryland
Not yet recruiting - verified May 2015

Pulmonary Embolism Diagnosis: Ultrasound Wells Score vs Traditional Wells Score

Condition:   Pulmonary Embolism
Intervention:  
Sponsor:   Azienda Ospedaliero-Universitaria Careggi
Recruiting - verified May 2015

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2015

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified May 2015

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2015

Venous Thromboembolic Prophylaxis After Major Trauma: A Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

Conditions:   Venous Thromboembolic Disease;   Deep Vein Thrombosis;   Pulmonary Embolism
Interventions:   Drug: 5000 Units unfractionated Heparin Q 8 hours;   Drug: 30mg enoxaparin Q12 hours
Sponsor:   Scripps Health
Active, not recruiting - verified September 2014

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2015

Pulmonary Embolism Response to Fragmentation, Embolectomy, & Catheter Thrombolysis: PERFECT

Condition:   Pulmonary Embolism
Intervention:   Procedure: Catheter directed debulking of Pulmonary Embolus
Sponsors:   Stanford University;   Adventist Midwest Health;   Weill Medical College of Cornell University;   Maine Medical Center;   Memorial Hospital of South Bend;   Northside Hospital, Inc.;   Universidad de Zaragoza
Recruiting - verified May 2015

A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days

Condition:   Thromboembolism
Intervention:   Drug: Pradax
Sponsors:   Nova Scotia Health Authority;   Ross K Leighton MD FRCSC
Withdrawn - verified May 2009

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

Conditions:   Venous Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Tinzaparin
Sponsors:   St. Joseph's Healthcare Hamilton;   Heart and Stroke Foundation of Ontario;   LEO Pharma
Recruiting - verified May 2015

Get CardioSmart

You're Invited